| Literature DB >> 17496999 |
Pankaj K Sharma1, H Rehwani, A K Rai, R S Gupta, Y P Singh.
Abstract
Triphenylantimony(V) derivative, Ph(3)Sb(OPr(i)) [SC(6)H(4)N : C(CH(3))CH(2)C(O)CH(3)], 1b, and the corresponding benzothiazoline ligand [1, 2], HNC(6)H(4)SC(CH(3))CH(2)C(O)CH(3), 1a, have been tested for their effects on the reproductive system of male albino rats. The oral administration of both 1a and 1b at the dose level of 10 mg/rat/day produced significant reduction in the weights of testes, epididymides, seminal vesicles, and ventral prostate. Significant decrease in sperm motility as well as in sperm density resulted in 100% sterility. Significant (P < .01) alterations were also found in biochemical parameters of reproductive organs in treated male rats as compared to the control group. Production of preleptotene, pachytene, and secondary spermatocytes was decreased by 42%, 43%, 39%, and by 44%, 49%, 55% in the ligand, 1a, and organoantimony(V) derivative, 1b, treated rats, respectively. These results indicate that both compounds 1a and 1b are antispermatogenic in nature and on oral administration in male rats, and finally caused sterility. A comparison indicates that the organoantimony(V) derivative 1b is more effective pertaining to its antispermatogenic activity than the corresponding ligand 1a.Entities:
Year: 2006 PMID: 17496999 PMCID: PMC1686299 DOI: 10.1155/BCA/2006/16895
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Effects of compounds 1a and 1b on body and organs weight in male rats.
| Treatment | Final body weight (g) | Organs weight (mg/100 gbwt) | |||
| Testes | Epididymides | Seminal vesicles | Ventral prostate | ||
|
| |||||
| Group-I | 230±5.65 | 1390±20.50 | 640.25 ± 24 | 690.40 ± 16.80 | 475.100 ± 12.5 |
| Control | |||||
| Group-II | 197.5 | 1286.52 | 524.57 | 582.84 | 299.14 |
| P1 treated | |||||
| Group-III | 187.5 | 1208.18 | 466.80 | 554.17 | 265.85 |
| P2 treated | |||||
All values are expressed as mean ± SE, ns: nonsignificant
Level of significance * P < .01; * P < .001 compared to control group
a P < .01; b P < .001 compared to P1 treated group.
Effect of compounds 1a and 1b on sperm motility and number in male rats.
| Treatment | Sperm motility (%) | Sperm density (million/mL) | Fertility (%) | Testosterone ng/dL | |
| Cauda epididymides | Testes | Cauda epididymides | |||
|
| |||||
| Group-I | 68.00 ± 1.10 | 4.10 ± 0.45 | 45.45 ± 0.95 | 100 %(+ve) | 5.25 + 0.05 |
| Control | |||||
| Group-II | 27.16 | 2.65 | 12.65 | 100 %(−ve) | 2.40 + 0.48 |
|
| |||||
| Group-III | 21.12 | 1.90 | 8.40 | 100 % (−ve) | 1.02 + 0.12 |
|
| |||||
All values are expressed as mean ± SE
Level of significance * P < .01; ** P < .001 compared to control group
a P < .01 compared to 1a treated group.
Effect of compounds 1a and 1b on biochemical parameters in male rats.
| Treatment | Protein (mg/g) | Sialic acid (mg/g) | Glycogen (mg/g) | Cholesterol (mg/g) | Fructose (mg/g) | ||||||
|
| |||||||||||
| Testes | Cauda epididymides | Seminal vesicle | Ventral prostate | Testes | Cauda epididymides | Ventral prostate | Seminal vesicle | Testes | Testes | Seminal vesicle | |
|
| |||||||||||
| Group-I | 244.05 | 224.40 | 212.45 | 208.0 | 5.18 | 6.05 | 5.45 | 5.68 | 3.40 | 5.28 | 4.65 |
| Control | ±3.65 | ±2.98 | ±3.50 | ±2.05 | ±0.12 | ±0.08 | ±0.10 | ±0.18 | ±0.18 | ±0.51 | ±0.10 |
| Group-II | 185.35 | 200.6 | 198.60 | 182.0 | 4.42 | 5.74 | 4.75 | 5.18 | 2.48 | 12.53 | 3.00 |
|
| ±2.05 | ±0.80 | ±1.05 | ±2.02 | ±0.2 | ±0.11 | ±0.09 | ±0.02 | ±0.22 | ±1.62 | ±0.11 |
| Group-III | 167.00 | 190.28 | 191.25 | 179.5 | 4.14 | 5.27 | 4.47 | 4.80 | 2.16 | 14.18 | 2.77 |
|
| ±4.42 | ±3.05 | 1.65 | ±1.88 | ±0.10 | ±0.08 | ±0.20 | ±0.05 | ±0.19 | ±2.08 | ±0.25 |
All values are expressed as mean ± SE
Level of significance * P < .01; ** P < .001 compared to control group.
a P < .01; b P < .001 compared to 1a treated group.
Effect of compounds 1a and 1b on testicular cell population dynamics.
| Treatment | Testicular cell counts (number/10 cross-section) | Seminiferous tubular diameter ( | ||||
|
| ||||||
| Sertoli cell | Spermatogonia | Preleptotene spermatocyte | Pachytene spermatocyte | Secondary sprermatocyte | ||
|
| ||||||
| Group-I | 2.79 ± 0.05 | 6.97 ± 0.77 | 22.82 ± 1.11 | 36.42 ± 1.37 | 48.50 ± 2.85 | 250.80 ± 6.68 |
| Control | ||||||
| Group-II | ||||||
| P1 treated | 2.45 | 5.89 ± 0.03 | 13.25 | 20.56 | 29.55 | 215.25 |
| Percent | (−12%) | (−15%) | (−42%) | (−43%) | (−39%) | (−14%) |
| deviation | ||||||
| Group-III | ||||||
| P2 treated | 2.32 | 5.92 ± 0.72 | 14.80 | 18.61 | 21.93 | 176.09 |
| Percent | (−17%) | (−15%) | (−44%) | (−49%) | (−55%) | (−30%) |
| deviation | ||||||
All values are expressed as mean ± SE
Level of significance * P < .01; ** P < .001 compared to control group.
a P < .01; b P < .001 compared to 1a treated group.
EValues in parentheses are percentage reduction in particular cell type.